Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.
Radiopharmacies Market Forecast Highlighting Growth From $11.12 Billion To $15.26 Billion
The radiopharmacies market size has shown substantial growth over recent years. It is anticipated to increase from $10.3 billion in 2025 to $11.12 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 8.0%. Historically, this expansion has been driven by the rising prevalence of cancer and various chronic diseases, the growing adoption of nuclear medicine imaging procedures, an increasing need for accurate diagnostic radiopharmaceuticals, the expansion of nuclear medicine departments in hospitals, and a heightened regulatory focus on the safe handling of radioactive materials.
The radiopharmacies market is projected to experience substantial expansion in the coming years. This market is forecast to reach $15.26 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 8.2%. This anticipated growth during the forecast timeframe is primarily driven by the increasing creation of targeted radionuclide treatments, enhanced investment in PET and SPECT imaging technologies, the broadening scope of personalized medicine uses, the increased formation of centralized radiopharmacy networks, and the escalating need for sophisticated radiopharmaceutical logistics and cold chain management. Key trends expected over the forecast period encompass an escalating requirement for targeted radiopharmaceutical treatments in oncology, the expanding use of centralized radiopharmacy services for streamlined dose compounding, a heightened emphasis on radiation safety and adherence to regulations within radiopharmacies, the broadening utility of nuclear medicine in cardiology and neurology, and increased capital allocation for sophisticated quality control and assurance frameworks for radiopharmaceutical management.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample_request?id=77240583&type=smp
Radiopharmacies Market Growth Drivers: What Factors Are Accelerating Expansion?
The increasing occurrence of cancer and chronic diseases is anticipated to propel the expansion of the radiopharmacies market in the future. These conditions refer to enduring health issues, including cancer, diabetes, heart disease, and respiratory illnesses, which demand continuous medical attention and can persist for months or years. The prevalence of cancer and chronic diseases is rising due to aging populations, as the risk of developing long-term ailments like cancer, diabetes, and heart disease naturally escalates with age. Radiopharmacies facilitate the diagnosis and treatment of cancer and chronic diseases by producing and supplying specialized radioactive drugs utilized in medical imaging and targeted therapies, enabling precise detection, monitoring, and treatment of these conditions. For instance, in February 2024, the World Health Organization, a Switzerland-based international organization specializing in global health policy and public health initiatives, predicted over 35 million new cancer cases in 2050, indicating a 77% increase from the estimated 20 million cases in 2022. Therefore, the growing prevalence of cancer and chronic diseases is driving the growth of the radiopharmacies market.
Radiopharmacies Market Segment Analysis Highlighting Growth Areas
The radiopharmacies market covered in this report is segmented –
1) By Product Type: Diagnostic Radiopharmaceuticals, Therapeutic Radiopharmaceuticals
2) By Service Type: Radiopharmaceutical Compounding, Dose Preparation, Nuclear Medicine Drug Dispensing, Quality Control And Assurance, Radiation Safety Management, Logistics And Delivery, Inventory Management, Regulatory Compliance Support, Consulting And Training Services
3) By Radioisotope Type: Technetium-Based Radiopharmaceuticals, Fluorine-Based Radiopharmaceuticals, Iodine-Based Radiopharmaceuticals, Gallium-Based Radiopharmaceuticals, Lutetium-Based Radiopharmaceuticals, Other Radioisotope Types
4) By Application: Oncology, Cardiology, Neurology, Endocrinology, Other Applications
5) By End User: Hospitals, Diagnostic Imaging Centers, Research Institutes, Specialty Clinics
Subsegments:
1) By Diagnostic Radiopharmaceuticals: Single Photon Emission Computed Tomography Radiopharmaceuticals, Positron Emission Tomography Radiopharmaceuticals, Bone Imaging Radiopharmaceuticals, Cardiac Imaging Radiopharmaceuticals, Renal Imaging Radiopharmaceuticals
2) By Therapeutic Radiopharmaceuticals: Radioiodine Therapy Radiopharmaceuticals, Radiolabeled Antibody Therapy, Peptide Receptor Radionuclide Therapy, Bone Pain Palliation Radiopharmaceuticals, Liver Cancer Therapy Radiopharmaceuticals
Radiopharmacies Market Trends: What Is Shaping Future Industry Growth?
Leading companies in the radiopharmacies market are focusing on developing innovative initiatives like advanced radiopharmaceutical production facilities to enhance manufacturing efficiency and ensure a reliable supply of diagnostic and therapeutic radiopharmaceuticals. These advanced facilities are specialized centers that produce radioactive compounds for medical imaging and therapy with high precision and safety, helping to guarantee consistent quality, faster production, and a dependable supply of diagnostic and therapeutic radiopharmaceuticals. For example, in October 2024, PharmaLogic Holdings Corp., a US-based manufacturing company, opened a state-of-the-art radiopharmaceutical production facility in Los Angeles to increase its capacity to provide critical imaging agents. The facility is equipped with automated synthesis modules, stringent quality control protocols, and scalable production lines, enabling consistent and high-purity radiotracer manufacturing. It supports the production of PET and SPECT imaging agents, reducing human error, minimizing contamination risks, and improving turnaround times compared to conventional laboratories.
Radiopharmacies Market Leading Companies: Who Holds Significant Market Presence?
Major companies operating in the radiopharmacies market are Cardinal Health Inc., Siemens Healthineers AG, GE HealthCare Technologies Inc., BWX Technologies Inc., Bracco Imaging S. p. A., Lantheus Holdings Inc., China Isotope & Radiation Corporation, Ion Beam Applications S. A. (IBA), Telix Pharmaceuticals Limited, Eckert & Ziegler Strahlen, PharmaLogic Holdings Corp., Shine Technologies LLC, NTP Radioisotopes SOC Ltd., NorthStar Medical Radioisotopes LLC, ITM Isotope Technologies Munich SE, ARTBIO Inc., Isotopia Molecular Imaging Ltd., AdvanCell Isotopes Pty Ltd, Futurechem Co. Ltd., Jubilant Radiopharma Pvt. Ltd., Cyclotek (Aust) Pty Ltd., Radiomedix Inc., Iso‑Tex Diagnostics Inc., Nucleus RadioPharma Inc.
Access The Complete Radiopharmacies Market Report:
https://www.thebusinessresearchcompany.com/report/radiopharmacies-market-report
Radiopharmacies Market Global Footprint: Which Region Holds Market Leadership?
North America was the largest region in the radiopharmacies market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the radiopharmacies market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Wasay has over a decade of experience in market research, data modelling, and analytics, with prior experience at GlobalData and Decision Tree Consulting Services. At The Business Research Company , he leads research operations across syndicated studies, customized consulting engagements, and the Global Market Model platform. His professional experience includes supporting organizations such as Boston Consulting Group, KPMG, and Ernst & Young. Wasay holds a degree in Electronics and Communications Engineering, postgraduate management qualifications from International Management Institute Belgium and Indian School of Business and Entrepreneurship, and completed the Integrated Program in Business Analytics from Indian Institute of Management Indore.